Anti-EVC2 monoclonal antibody

Pre-made anti-EVC2 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to EVC2/EVC2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0777-Ab-1/ GM-Tg-hg-IP0777-Ab-2Anti-Human EVC2 monoclonal antibodyHuman
GM-Tg-rg-IP0777-Ab-1/ GM-Tg-rg-IP0777-Ab-2Anti-Rat EVC2 monoclonal antibodyRat
GM-Tg-mg-IP0777-Ab-1/ GM-Tg-mg-IP0777-Ab-2Anti-Mouse EVC2 monoclonal antibodyMouse
GM-Tg-cynog-IP0777-Ab-1/ GM-Tg-cynog-IP0777-Ab-2Anti-Cynomolgus/ Rhesus macaque EVC2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0777-Ab-1/ GM-Tg-felg-IP0777-Ab-2Anti-Feline EVC2 monoclonal antibodyFeline
GM-Tg-cang-IP0777-Ab-1/ GM-Tg-cang-IP0777-Ab-2Anti-Canine EVC2 monoclonal antibodyCanine
GM-Tg-bovg-IP0777-Ab-1/ GM-Tg-bovg-IP0777-Ab-2Anti-Bovine EVC2 monoclonal antibodyBovine
GM-Tg-equg-IP0777-Ab-1/ GM-Tg-equg-IP0777-Ab-2Anti-Equine EVC2 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0777-Ab-1/ GM-Tg-hg-IP0777-Ab-2; GM-Tg-rg-IP0777-Ab-1/ GM-Tg-rg-IP0777-Ab-2;
GM-Tg-mg-IP0777-Ab-1/ GM-Tg-mg-IP0777-Ab-2; GM-Tg-cynog-IP0777-Ab-1/ GM-Tg-cynog-IP0777-Ab-2;
GM-Tg-felg-IP0777-Ab-1/ GM-Tg-felg-IP0777-Ab-2; GM-Tg-cang-IP0777-Ab-1/ GM-Tg-cang-IP0777-Ab-2;
GM-Tg-bovg-IP0777-Ab-1/ GM-Tg-bovg-IP0777-Ab-2; GM-Tg-equg-IP0777-Ab-1/ GM-Tg-equg-IP0777-Ab-2
Products NameAnti-EVC2 monoclonal antibody
Formatmab
Target NameEVC2
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-EVC2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0777-Ag-1Recombinant multi-species LBN/ EVC2/ WAD protein


    Target information

    Target IDGM-IP0777
    Target NameEVC2
    Gene ID132884,68525,289711,722758,611156,101092761,280834,100069979
    Gene Symbol and Synonyms1110017L09Rik,EVC2,LBN,limbin,WAD
    Uniprot AccessionQ86UK5,Q8MI28
    Uniprot Entry NameLBN_HUMAN,LBN_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000173040
    Target ClassificationN/A

    The target: EVC2, gene name: EVC2, also named as LBN, WAD. This gene encodes a protein that functions in bone formation and skeletal development. Mutations in this gene, as well as in a neighboring gene that lies in a head-to-head configuration, cause Ellis-van Creveld syndrome, an autosomal recessive skeletal dysplasia that is also known as chondroectodermal dysplasia. Mutations in this gene also cause acrofacial dysostosis Weyers type, also referred to as Curry-Hall syndrome, a disease that combines limb and facial abnormalities. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.